Dosing begins in Phase 2a trial of foralumab nasal spray for SPMS
Tiziana Life Sciences has dosed the first patient in a Phase 2a clinical trial testing its foralumab nasal spray in…
Articles by Patricia Inacio, PhD
‘Multifactorial’ approach may be needed to prevent falls in MS: Study
The risk of falling among people with multiple sclerosis (MS) seems to be associated with a combination of personal,…
Vanda acquires rights to Ponvory for MS in US, Canada for $100M
Vanda Pharmaceuticals has acquired the U.S. and Canadian rights to Ponvory (ponesimod), an oral therapy approved for relapsing types…
Aerobic cycling eases fatigue and pain of MS, if intensity kept up
Adhering to an aerobic exercise program of moderate to intense cycling for 12 weeks significantly eased pain and fatigue in…
InSilicoTrials wins award for its AI efforts in treatment development
InSilicoTrials (IST) has received this year’s Innovation Radar Prize for its efforts to harness artificial intelligence (AI) to advance…
Better sleep linked to quality of life, mental health in children with MS
In children with pediatric-onset multiple sclerosis (POMS), poor sleep quality is linked to fatigue, depression, and worse quality of…
Losing sense of smell can predict MS relapse-independent progression
Losing the sense of smell is associated with a higher likelihood of worse disease outcomes for people with multiple…
Sativex reimbursed in Ireland for eligible MS patients with spasticity
Nabiximols, the cannabis-based oral spray sold as Sativex, is available for reimbursement as an add-on therapy for moderate to…
Vidofludimus calcium reduced NfL levels in progressive MS patients
Vidofludimus calcium (IMU-838), an investigational oral therapy being developed by Immunic Therapeutics for all types of multiple sclerosis…
Switching DMTs in MS found to impact relapse risk in real world
People with multiple sclerosis (MS) who switch between more than two disease-modifying therapies (DMTs) have a higher risk…
Google Maps Timeline may help in monitoring walking ability in MS
Assessing a person’s daily walking patterns using the Google Maps Timeline tool may help doctors remotely monitor fatigue, walking ability,…
Data: Lucid-MS seen to be safe, well tolerated in healthy volunteers
FSD Pharma’s Lucid-21-302 — an oral treatment candidate known as Lucid-MS, for all types of multiple sclerosis (MS)…
Fatigue not eased with DMTs in people with MS: Study
Using disease-modifying therapies (DMTs) doesn’t reduce fatigue levels in people with multiple sclerosis (MS), a study in Norway…
FDA clears first clinical study of investigational therapy LPX-TI641
Lapix Therapeutics is launching a Phase 1 clinical trial to evaluate LPX-TI641, its investigational treatment for autoimmune diseases such…
First of its kind algorithm may help predict treatment adherence in MS
Swoop, a consumer health data company, is launching a first of its kind algorithm that’s designed to predict treatment…
About 1 in 4 MS patients experience migraines: Review study
People with multiple sclerosis (MS) are about two times more likely to have migraines than healthy people while migraines…
Bowel problems often unreported by MS patients to their doctors
Bowel symptoms go largely unreported among people with multiple sclerosis (MS), mostly due to the unwillingness of patients to…
Ocrevus now publicly funded for PPMS in New Zealand
Ocrevus (ocrelizumab) will be funded in New Zealand for treating certain people with primary progressive multiple sclerosis (PPMS)…
Neural Sleeve wins multiple honors for excellence in design this year
Cionic’s Neural Sleeve, a leg-worn garment designed to boost strength and walking performance in people with conditions such as multiple…
Progressive MS trial of vidofludimus calcium fully enrolled
A global Phase 2 clinical trial investigating the oral therapy vidofludimus calcium (IMU-838) in people with progressive forms of…
Disability leads to great costs for patients, society: Real-world data
Disability progression in people with multiple sclerosis (MS) significantly reduces their quality of life, affects their ability to work,…
DMT use does not seem to affect sleep quality, daytime sleepiness
The use of disease-modifying therapies (DMTs) does not seem to affect sleep quality or daytime sleepiness in people with…
Cow milk proteins likely trigger of broader immune response with MS
A significantly higher immune response against proteins found in cow milk is evident in people with multiple sclerosis (MS),…
New deal grants Neuraxpharm rights to market Briumvi in Europe
The specialty pharmaceutical company Neuraxpharm will be responsible for marketing the multiple sclerosis (MS) therapy Briumvi (ublituximab) in…
Benefits of ketogenic diet in RRMS may be long lasting: Study
Following a ketogenic diet — one that’s low in carbohydrates and rich in fat — for six months significantly reduced…
Primary progressive MS can greatly reduce life quality, ability to work
Primary progressive multiple sclerosis (PPMS) can greatly reduce quality of life for patients and affect their ability to work,…
RRMS patients with high chloride levels may be at more relapse risk
Relapsing-remitting multiple sclerosis (RRMS) patients with elevated levels of chloride in their cerebrospinal fluid (CSF), the fluid that bathes…
Potentially safer MRI gadolinium-based contrast agent to enter testing
Gadoquatrane, a gadolinium-based contrast agent (GBCA) that may be safer than current agents for people undergoing MRI scans, has…
Cigarette smoking slows recovery after an MS relapse, study finds
Cigarette smoking significantly slows recovery time from a relapse for people with relapsing-remitting multiple sclerosis (RRMS), according to a…
Stopping DMTs a ‘reasonable option’ for some older MS patients
Older people with multiple sclerosis (MS) who have not experienced disease activity for several years still will benefit from…